UKUK

Researchers heal prostate cancer with novel cancer immune therapy

20.06.2011

Leeds –UK researchers have cured mice xenografted with human prostate tumours with a new immune therapy approach. Until now, immune therapy approaches have been highly unsuccessful as each tumour has specific proteins and identifying the right antigens has been a huge challenge. However, researchers headed by Alan Melcher from University of Leeds and US researchers from Mayo Clinic in Rochester have solved this problem by expressing a virally expressed epitope library (VEEL) from normal human prostate. In mice, the researchers detected no autoimmunity. Furthermore, tumours that escaped immune selection adopted a new phenotype and could be treated with a second-line therapy. Most importantly, the DNA library which was expressed in the highly immunogenic vesicular stomatitis virus (VSV), made the immune system 'self-select' the cancer antigens to which to respond and did not react against other healthy parts of the body. Also, the process of self-selection was triggered when the vaccine was injected into the bloodstream, an approach to vaccination that is far more practical than injecting directly into tumours. According to the researchers, use of the cDNA library led to presentation of a broad repertoire of undefined tumour-associated antigens, which reduced emergence of treatment-resistant variants and will permit rational, combined-modality approaches in the clinic.

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1983

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/researchers-heal-prostate-cancer-with-novel-cancer-immune-therapy.html

Product of the week

Products

Events

All Events

Current issue

All issues